uniQure (NASDAQ:QURE) Director Madhavan Balachandran Sells 10,000 Shares

uniQure N.V. (NASDAQ:QURE) Director Madhavan Balachandran sold 10,000 shares of uniQure stock in a transaction on Monday, June 15th. The shares were sold at an average price of $27.85, for a total transaction of $278,500.00. Following the completion of the transaction, the director directly owned 43,254 shares in the company, valued at $1,204,623.90. The trade was a 18.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Madhavan Balachandran also recently made the following trade(s):

• On Thursday, June 11th, Madhavan Balachandran sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58.

uniQure Stock Performance

Shares of uniQure stock opened at $48.16 on Thursday. The firm’s fifty day simple moving average is $23.55 and its 200-day simple moving average is $21.90. The stock has a market capitalization of $3.04 billion, a price-to-earnings ratio of -13.84 and a beta of 0.98. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. As a group, equities analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on QURE shares. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. HC Wainwright lowered their price objective on shares of uniQure from $70.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Chardan Capital lifted their price objective on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Royal Bank Of Canada upgraded shares of uniQure from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $11.00 to $35.00 in a research report on Monday, March 9th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $35.00 price objective on shares of uniQure in a research report on Monday, March 2nd. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and an average target price of $47.17.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently made changes to their positions in QURE. Torren Management LLC purchased a new stake in shares of uniQure during the 4th quarter worth $28,000. Jones Financial Companies Lllp boosted its position in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares in the last quarter. IFP Advisors Inc purchased a new stake in shares of uniQure during the 4th quarter worth $48,000. Smartleaf Asset Management LLC purchased a new stake in shares of uniQure during the 4th quarter worth $48,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in shares of uniQure during the 3rd quarter worth $50,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: FDA feedback now appears to support a near-term BLA submission for AMT-130, improving the odds of accelerated approval for Huntington’s disease. Reuters
• Positive Sentiment: Cantor Fitzgerald upgraded uniQure to Overweight, citing the improved regulatory outlook and raising its price target to $61. Seeking Alpha
• Neutral Sentiment: The company disclosed insider sales by directors and executives, including recent transactions by Madhavan Balachandran and Jeannette Potts, which may draw attention but were executed under a pre-arranged trading plan in at least one case.
• Neutral Sentiment: Analyst opinions remain mixed overall, with recent price targets ranging widely, showing that expectations for the stock are still highly dependent on FDA and clinical execution.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.